Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer
BackgroundIn patients with hormone receptor-positive (HR+)/premenopausal breast cancer, luteinizing hormone-releasing hormone analogs (LHRHas) are used as standard endocrine treatment. Based on previous clinical studies, 1-month formulations are recommended in most breast cancer treatment guidelines...
Main Authors: | Zhen-Yu Wu, Young-jin Lee, Heejeong Kim, Jongwon Lee, Il Yong Chung, Jisun Kim, Saebyeol Lee, Byung-Ho Son, Sung-Bae Kim, Jae Ho Jeong, Gyungyub Gong, Sei-Hyun Ahn, BeomSeok Ko |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.665426/full |
Similar Items
-
Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty
by: You Jin Kim, et al.
Published: (2013-12-01) -
The comparative evaluation of apoptosis produced by leuprolide or orchiectomy on rat prostate tissue
by: Basri Cakiroglu, et al.
Published: (2016-01-01) -
A Case of Leuprolide-Induced Posterior Reversible Encephalopathy Syndrome
by: Chae Young Lee, et al.
Published: (2016-12-01) -
Pharmacokinetic–Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats
by: Dong-Seok Lee, et al.
Published: (2018-04-01) -
Adjuvant Effect of Leuprolide on Stroke: A Case report
by: Carlo Sebastiano Tadeo, et al.
Published: (2014-11-01)